BioCentury | Aug 31, 2020
Deals

Three years after spinout, Ionis brings back Akcea in $500M acquisition

...the past 10 years, only one of which involved a pharma company: Pfizer’s purchase of Excaliard...
BioCentury | Nov 25, 2013
Company News

Lithera management update

...Diego, Calif. Business: Ophthalmic, Endocrine/Metabolic Hired: Lincoln Krochmal as CMO, formerly president and CEO of Excaliard Pharmaceuticals Inc....
BioCentury | Nov 12, 2012
Company News

Isis Pharmaceuticals, Pfizer deal

...into Phase II testing. Pfizer gained rights to EXC 001 through its 2011 acquisition of Excaliard Pharmaceuticals Inc....
...Isis' stake in Excaliard. Under the terms of the licensing deal for EXC 001 with Excaliard...
BioCentury | Jul 9, 2012
Emerging Company Profile

SironRX: Sealing scars

...a self-delivering rxRNA (sd-rxRNA) targeting CTGF. Pfizer gained PF-06473871 from its 2011 acquisition of Excaliard Pharmaceuticals Inc....
BioCentury | Dec 5, 2011
Company News

Excaliard, Pfizer deal

...Pfizer acquired skin scarring therapy company Excaliard for an undisclosed upfront payment, plus milestones. Pfizer will...
...treatments for fibrosis and tissue remodeling. The deal is expected to close by year end. Excaliard...
...Excaliard, which included a total of $47.7 million in milestones (see BioCentury, Dec. 3, 2007). Excaliard Pharmaceuticals Inc....
BioCentury | Nov 23, 2011
Company News

Pfizer to buy scarring play Excaliard

...Pfizer Inc. (NYSE:PFE) will acquire scarring therapy company Excaliard Pharmaceuticals Inc. (Carlsbad, Calif.) for an undisclosed upfront payment...
...end. Excaliard has rights to EXC 001 from Isis Pharmaceuticals Inc. (NASAQ:ISIS), which is an Excaliard...
...than 10%. Isis said it could receive up to $14 million from Pfizer's acquisition of Excaliard...
BioCentury | Jan 24, 2011
Clinical News

EXC 001: Phase II data

...well tolerated. Excaliard licensed EXC 001 from Isis in 2007 (see BioCentury, Dec. 3, 2007). Excaliard Pharmaceuticals Inc....
BioCentury | Oct 25, 2010
Company News

Excaliard board of directors update

Excaliard Pharmaceuticals Inc. , Carlsbad, Calif. Business: Dermatology Appointed: Thomas Wiggans as chairman; former chairman and CEO of Peplin Inc. , which was acquired by Leo Pharma A/S WIR Staff Dermatology...
BioCentury | Oct 19, 2010
Company News

Excaliard names Wiggans chairman

...Dermatology company Excaliard Pharmaceuticals Inc. (Carlsbad, Calif.) appointed Thomas Wiggans chairman. Wiggans is the former chairman and CEO...
BioCentury | Sep 6, 2010
Product Development

Anti-scarring antisense

...do so, the company expects the final data will show a robust treatment effect. Indeed, Excaliard...
...of CTGF expression could be more effective than other compounds in development for reducing scars. Excaliard...
...event, where it plays a critical role in directing collagen and other extracellular matrix proteins," Excaliard...
Items per page:
1 - 10 of 19
BioCentury | Aug 31, 2020
Deals

Three years after spinout, Ionis brings back Akcea in $500M acquisition

...the past 10 years, only one of which involved a pharma company: Pfizer’s purchase of Excaliard...
BioCentury | Nov 25, 2013
Company News

Lithera management update

...Diego, Calif. Business: Ophthalmic, Endocrine/Metabolic Hired: Lincoln Krochmal as CMO, formerly president and CEO of Excaliard Pharmaceuticals Inc....
BioCentury | Nov 12, 2012
Company News

Isis Pharmaceuticals, Pfizer deal

...into Phase II testing. Pfizer gained rights to EXC 001 through its 2011 acquisition of Excaliard Pharmaceuticals Inc....
...Isis' stake in Excaliard. Under the terms of the licensing deal for EXC 001 with Excaliard...
BioCentury | Jul 9, 2012
Emerging Company Profile

SironRX: Sealing scars

...a self-delivering rxRNA (sd-rxRNA) targeting CTGF. Pfizer gained PF-06473871 from its 2011 acquisition of Excaliard Pharmaceuticals Inc....
BioCentury | Dec 5, 2011
Company News

Excaliard, Pfizer deal

...Pfizer acquired skin scarring therapy company Excaliard for an undisclosed upfront payment, plus milestones. Pfizer will...
...treatments for fibrosis and tissue remodeling. The deal is expected to close by year end. Excaliard...
...Excaliard, which included a total of $47.7 million in milestones (see BioCentury, Dec. 3, 2007). Excaliard Pharmaceuticals Inc....
BioCentury | Nov 23, 2011
Company News

Pfizer to buy scarring play Excaliard

...Pfizer Inc. (NYSE:PFE) will acquire scarring therapy company Excaliard Pharmaceuticals Inc. (Carlsbad, Calif.) for an undisclosed upfront payment...
...end. Excaliard has rights to EXC 001 from Isis Pharmaceuticals Inc. (NASAQ:ISIS), which is an Excaliard...
...than 10%. Isis said it could receive up to $14 million from Pfizer's acquisition of Excaliard...
BioCentury | Jan 24, 2011
Clinical News

EXC 001: Phase II data

...well tolerated. Excaliard licensed EXC 001 from Isis in 2007 (see BioCentury, Dec. 3, 2007). Excaliard Pharmaceuticals Inc....
BioCentury | Oct 25, 2010
Company News

Excaliard board of directors update

Excaliard Pharmaceuticals Inc. , Carlsbad, Calif. Business: Dermatology Appointed: Thomas Wiggans as chairman; former chairman and CEO of Peplin Inc. , which was acquired by Leo Pharma A/S WIR Staff Dermatology...
BioCentury | Oct 19, 2010
Company News

Excaliard names Wiggans chairman

...Dermatology company Excaliard Pharmaceuticals Inc. (Carlsbad, Calif.) appointed Thomas Wiggans chairman. Wiggans is the former chairman and CEO...
BioCentury | Sep 6, 2010
Product Development

Anti-scarring antisense

...do so, the company expects the final data will show a robust treatment effect. Indeed, Excaliard...
...of CTGF expression could be more effective than other compounds in development for reducing scars. Excaliard...
...event, where it plays a critical role in directing collagen and other extracellular matrix proteins," Excaliard...
Items per page:
1 - 10 of 19